<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04043273</url>
  </required_header>
  <id_info>
    <org_study_id>SATIS-Fab</org_study_id>
    <nct_id>NCT04043273</nct_id>
  </id_info>
  <brief_title>Treatment-related Benefit and Satisfaction in Fabry Patients. Insight in Patients Expectations and Preferences</brief_title>
  <official_title>Treatment-related Benefit and Satisfaction in Fabry Patients. Insight in Patients Expectations and Preferences (SATIS-Fab)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics France SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics France SAS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the shared decision-making process, patients should express their expectations and
      preferences regarding treatment to the physician. A specific questionnaire addressing needs
      and expectations of Fabry patients has been built at the initiative of Amicus. In addition,
      this questionnaire also evaluates the benefit of treatment from the patient's perspective.
      Nothing is known until now on patient's expectations, potential clustering of patients
      regarding their expectations and evaluation of treatment benefit from the patients
      perspective.

      Study objectives are differentiated according to the study phase (inclusion and follow-up).
      At inclusion, the primary objective is to cluster patients according to their needs and
      expectations regarding treatment. During follow-up, the primary objective is to evaluate
      treatment benefit in relation with patients needs and expectations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, longitudinal, non-comparative, open-label, multicentre, non interventional
      cohort study. Decision to treat the patient should be made independently of the patient's
      participation in the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Homogeneous clusters of patients according to their needs and expectations towards the treatment received.</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of clusters will be defined using a non-supervised classification method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate treatment benefit in relation to patients needs and expectations towards their specific treatment.</measure>
    <time_frame>12 month</time_frame>
    <description>Patients Benefit Index (PBI): descriptive statistics. The PBI will be calculated by reference to the PNQ measured at the preceding visit
The proportion of patients with PBI ≥ 1 will be described with a two-sided 95% confidence interval.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Fabry Disease</condition>
  <condition>Anderson Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Whole cohort</arm_group_label>
    <description>The whole cohort will be divided into clusters according to patients expectations and preferences regarding their treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Characterization of patients expectations and preferences regarding their treatment</intervention_name>
    <description>Patients will be clustered before and after a principal components analysis (PCA) on PNQ. Observations will be clustered by the Ward method. The number of clusters will be chosen using the Kolinski criteria. Characteristics of patients will be described by cluster.</description>
    <arm_group_label>Whole cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be clustered before and after a principal components analysis (PCA) on PNQ.
        Observations will be clustered by the Ward method. The number of clusters will be chosen
        using the Kolinski criteria. Characteristics of patients will be described by cluster.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 16 years old

          -  Diagnosed with Fabry disease

          -  With amenable mutation

          -  Decision by clinician to start or pursue ongoing ERT or migalastat

          -  Non-opposition form to participate in the study signed

        Exclusion Criteria:

        - Concomitant patient participation in an interventional clinical study (Category 1
        interventional research or category 2 interventional research according to the Jardé law
        classification in France)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Lidove, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Diaconesses Croix Saint-Simon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier LIdove, MD</last_name>
    <phone>144643329</phone>
    <phone_ext>0033</phone_ext>
    <email>olidove@hopital-dcss.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Lavigne, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Lavigne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Lacombe, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achille Aouba, MD</last_name>
    </contact>
    <investigator>
      <last_name>Achille Aouba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Leguy-Seguin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de référence de la maladie de Fabry et des maladies héréditaires du tissu conjonctif</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Germain, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Hachulla, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Eric Hachulla, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène Maillard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Fouilhoux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand Dussol, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agathe Masseau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Agathe Masseau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine Dahan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Diaconesses Croix Saint-Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Lidove, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Lidove, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bérangère Cador, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soumeya Bekri, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Noel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grégory Pugnet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Maillot, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

